243 related articles for article (PubMed ID: 32128670)
21. A case of hepatocellular carcinoma with pseudoaneurysm formation upon lenvatinib administration.
Yano R; Hirooka M; Nakamura Y; Imai Y; Koizumi Y; Watanabe T; Yoshida O; Tokumoto Y; Abe M; Hiasa Y
Clin J Gastroenterol; 2024 Apr; 17(2):319-326. PubMed ID: 38281290
[TBL] [Abstract][Full Text] [Related]
22. Permanent hypothyroidism following immune checkpoint inhibitors induced thyroiditis may be associated with improved survival: results of an exploratory study.
Lee HJ; Manavalan A; Stefan-Lifshitz M; Schechter C; Maity A; Tomer Y
Front Endocrinol (Lausanne); 2023; 14():1169173. PubMed ID: 37168978
[TBL] [Abstract][Full Text] [Related]
23. Clinical characteristics of thyroid abnormalities induced by sunitinib treatment in Japanese patients with renal cell carcinoma.
Sato S; Muraishi K; Tani J; Sasaki Y; Tokubuchi I; Tajiri Y; Yamada K; Suekane S; Miyajima J; Matsuoka K; Hiromatsu Y
Endocr J; 2010; 57(10):873-80. PubMed ID: 20733268
[TBL] [Abstract][Full Text] [Related]
24. Lenvatinib: a potential breakthrough in advanced hepatocellular carcinoma?
Oikonomopoulos G; Aravind P; Sarker D
Future Oncol; 2016 Feb; 12(4):465-76. PubMed ID: 26785762
[TBL] [Abstract][Full Text] [Related]
25. Change in arterial tumor perfusion is an early biomarker of lenvatinib efficacy in patients with unresectable hepatocellular carcinoma.
Kuorda H; Abe T; Fujiwara Y; Okamoto T; Yonezawa M; Sato H; Endo K; Oikawa T; Sawara K; Takikawa Y
World J Gastroenterol; 2019 May; 25(19):2365-2372. PubMed ID: 31148907
[TBL] [Abstract][Full Text] [Related]
26. Sorafenib induced thyroiditis in two patients with hepatocellular carcinoma.
van Doorn L; Eskens FA; Visser TJ; van der Lugt A; Mathijssen RH; Peeters RP
Thyroid; 2011 Feb; 21(2):197-202. PubMed ID: 21275767
[TBL] [Abstract][Full Text] [Related]
27. Factors Raising Serum Ammonia Level During Lenvatinib Treatment of Patients With Hepatocellular Carcinoma.
Narita R; Kotoh K; Yoneda A; Motomura M; Harada M
Anticancer Res; 2020 Sep; 40(9):5271-5276. PubMed ID: 32878816
[TBL] [Abstract][Full Text] [Related]
28. Optimal management of patients with hepatocellular carcinoma treated with lenvatinib.
Ikeda M; Kobayashi M; Tahara M; Kaneko S
Expert Opin Drug Saf; 2018 Nov; 17(11):1095-1105. PubMed ID: 30264594
[TBL] [Abstract][Full Text] [Related]
29. Lenvatinib-induced Interstitial Pneumonia in a Patient with Hepatocellular Carcinoma.
Imakura T; Sato S; Tomonari T; Murakami K; Takahashi N; Naito N; Mima M; Kagawa K; Koyama K; Nishimura H; Kawano H; Nokihara H; Azuma M; Takayama T; Nishioka Y
Intern Med; 2022 Apr; 61(8):1211-1217. PubMed ID: 34544944
[TBL] [Abstract][Full Text] [Related]
30. The Geriatric Nutritional Risk Index Predicts Tolerability of Lenvatinib in Patients With Hepatocellular Carcinoma.
Kinoshita A; Hagiwara N; Osawa A; Akasu T; Matsumoto Y; Ueda K; Saeki C; Oikawa T; Koike K; Saruta M
In Vivo; 2022; 36(2):865-873. PubMed ID: 35241544
[TBL] [Abstract][Full Text] [Related]
31. Sunitinib (sutent)-induced thyrotoxicosis due to destructive thyroiditis: a case report.
Faris JE; Moore AF; Daniels GH
Thyroid; 2007 Nov; 17(11):1147-9. PubMed ID: 17714037
[TBL] [Abstract][Full Text] [Related]
32. Lenvatinib for hepatocellular carcinoma: From preclinical mechanisms to anti-cancer therapy.
Zhao Y; Zhang YN; Wang KT; Chen L
Biochim Biophys Acta Rev Cancer; 2020 Aug; 1874(1):188391. PubMed ID: 32659252
[TBL] [Abstract][Full Text] [Related]
33. Phase 2 study of lenvatinib in patients with advanced hepatocellular carcinoma.
Ikeda K; Kudo M; Kawazoe S; Osaki Y; Ikeda M; Okusaka T; Tamai T; Suzuki T; Hisai T; Hayato S; Okita K; Kumada H
J Gastroenterol; 2017 Apr; 52(4):512-519. PubMed ID: 27704266
[TBL] [Abstract][Full Text] [Related]
34. Camrelizumab combined with lenvatinib in the treatment of gastric cancer with liver metastasis: a case report.
Wang K; Wang H; Lv Y; Liu H; Liu J; Zhang Y
Ann Palliat Med; 2021 Jan; 10(1):803-809. PubMed ID: 33545802
[TBL] [Abstract][Full Text] [Related]
35. Sorafenib Rechallenge and Sorafenib after Lenvatinib Failure in a Patient with Hepatocellular Carcinoma.
Ikeda A; Aoki K; Kawamura M; Yamaguchi D; Kokuryu H
Intern Med; 2021; 60(3):403-407. PubMed ID: 33518611
[TBL] [Abstract][Full Text] [Related]
36. Lenvatinib-Induced Tumor-Related Hemorrhages in Patients with Large Hepatocellular Carcinomas.
Uchida-Kobayashi S; Kageyama K; Yamamoto A; Ikenaga H; Yoshida K; Kotani K; Kimura K; Odagiri N; Hagihara A; Fujii H; Enomoto M; Tamori A; Kubo S; Miki Y; Kawada N
Oncology; 2021; 99(3):186-191. PubMed ID: 33032274
[TBL] [Abstract][Full Text] [Related]
37. Early changes in ammonia levels and liver function in patients with advanced hepatocellular carcinoma treated by lenvatinib therapy.
Ohya K; Kawaoka T; Namba M; Uchikawa S; Kodama K; Morio K; Nakahara T; Murakami E; Hiramatsu A; Tsuge M; Yamauchi M; Imamura M; Chayama K; Aikata H
Sci Rep; 2019 Aug; 9(1):12101. PubMed ID: 31431642
[TBL] [Abstract][Full Text] [Related]
38. Correlation between Early Tumor Marker Response and Imaging Response in Patients with Advanced Hepatocellular Carcinoma Treated with Lenvatinib.
Kodama K; Kawaoka T; Namba M; Uchikawa S; Ohya K; Morio K; Nakahara T; Murakami E; Yamauchi M; Hiramatsu A; Imamura M; Chayama K; Aikata H
Oncology; 2019; 97(2):75-81. PubMed ID: 31242488
[TBL] [Abstract][Full Text] [Related]
39. Hepatocellular Carcinoma Rupture after Introducing Lenvatinib: An Autopsy Case Report.
Kohya R; Sugiura R; Yamamoto Y; Naruse H; Hatanaka K; Kinoshita K; Abiko S; Miyamoto S; Suzuki K; Kushibiki H; Munakata S; Shimoyama N
Intern Med; 2023 Apr; 62(7):995-998. PubMed ID: 36047124
[TBL] [Abstract][Full Text] [Related]
40. Pneumothorax during lenvatinib treatment for hepatocellular carcinoma with lung metastasis.
Kawanishi Y; Kuwahara M; Utsunomiya M; Ishida N; Ishikawa Y; Hiroi M; Akimori T
Clin J Gastroenterol; 2021 Feb; 14(1):288-292. PubMed ID: 33108567
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]